Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2026-02-21 @ 4:58 AM
Study NCT ID:
NCT02574533
Status:
COMPLETED
Last Update Posted:
2017-09-27
First Post:
2015-10-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Sponsor:
Gradalis, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CL-PTL-123
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None